EUROAPI Enhances Its CDMO Capabilities Through a Pivotal Collaboration With SpiroChem, a Leading Contract Research Organization (CRO)
25 Janvier 2024 - 7:00AM
Business Wire
- This collaboration will ensure the continuity of API
development, from route scouting to process industrialization and
GMP manufacturing
- EUROAPI and SpiroChem to provide clients with consolidated
CRO-CDMO customized solutions to accelerate API chemical
development and shorten timelines, especially for early-stage
projects and the biotech segment
- This agreement will strengthen EUROAPI’s Contract Development
and Manufacturing Organization (CDMO) roadmap through vertical
cooperation
Regulatory News:
EUROAPI (Paris:EAPI) announced today that it has initiated a
pivotal collaboration with SpiroChem, a leading Contract Research
Organization (CRO) with best-in-class status in the field of early
Chemical Process R&D (route scouting). SpiroChem is
headquartered in Basel, Switzerland.
SpiroChem and EUROAPI are joining forces to offer their
customers a consolidated CRO-CDMO solution, ensuring that
industrialization constraints for small molecules are integrated
from the initial step of drug design, thereby speeding up the
process.
Customers from both companies will benefit from SpiroChem’s
cutting-edge expertise and innovative solutions in route scouting
and EUROAPI’s industrialization strategy to develop the best
synthetic routes directly in line with scale-up feasibility,
quality, regulatory, environmental requirements, and economic
sustainability. The agreement will further differentiate both
companies’ value proposition as their customers will benefit from
both SpiroChem’s early-stage premium services and EUROAPI’s
development and GMP1 manufacturing capacities and skills.
“By adding a renowned CRO partner like SpiroChem to our existing
R&D and industrial offering, this fruitful collaboration will
strengthen our market position and accelerate our CDMO roadmap,”
said Cécile Maupas, Chief CDMO Officer of EUROAPI. “Together with
EUROAPI’s production technologies, SpiroChem’s recognized
capabilities in route scouting will enable us to provide customers
with integrated customized solutions to make their chemical drug
development shorter, greener and more cost-efficient.”
“Having EUROAPI as a partner brings a substantial value to
SpiroChem’s customers who are looking for reliable CDMOs to rapidly
and seamlessly scale up the innovative solutions developed by
SpiroChem,” said Thomas Fessard, CEO and co-founder of SpiroChem.
“Time is of the essence in early CMC2 and we are confident
that this collaboration will greatly benefit our customer base, in
particular by accelerating the transition from discovery to
development for early-stage projects and the biotech segment.”
About EUROAPI
EUROAPI is focused on reinventing active ingredient solutions to
sustainably meet customers’ and patients’ needs around the world.
We are a leading player in active pharmaceutical ingredients with
approximately 200 products in our portfolio, offering a large span
of technologies, while developing innovative molecules through our
Contract Development and Manufacturing Organization (CDMO)
activities.
Taking action for health by enabling access to essential
therapies inspires our 3,450 people every day. With strong research
and development capabilities and six manufacturing sites all
located in Europe, EUROAPI ensures API manufacturing of the highest
quality to supply customers in more than 80 countries. EUROAPI is
listed on Euronext Paris; ISIN: FR0014008VX5; ticker: EAPI). Find
out more at www.euroapi.com and follow us on LinkedIn.
About SpiroChem
SpiroChem is a Swiss CRO delivering the highest standards of
services in the discovery chemistry and early PR&D segment.
SpiroChem's elite chemistry team has a proven track record of
providing value and delivering solutions to biotech, pharma and
CDMO customers.
SpiroChem AG is a private company, spun-out from the Swiss
Federal Institute of Technology in 2011. It is headquartered in
Basel, Switzerland, with operations in Switzerland and Canada
(Montreal). Find out more about us at www.spirochem.com and on
LinkedIn.
EUROAPI Forward-Looking Statements
Certain information contained in this press release is forward
looking and not historical data. These forward-looking statements
are based on opinions, projections and current assumptions
including, but not limited to, assumptions concerning the Group’s
current and future strategy, financial and non-financial future
results and the environment in which the Group operates, as well as
events, operations, future services or product development and
potential. Forward-looking statements are generally identified by
the words “expects”, “anticipates”, “believes”, “intends”,
“estimates”, “plans” and similar expressions. Forward looking
statements and information do not constitute guarantees of future
performances, and are subject to known or unknown risks,
uncertainties and other factors, a large number of which are
difficult to predict and generally outside the control of the
Group, which could cause actual results, performances or
achievements, or the results of the sector or other events, to
differ materially from those described or suggested by these
forward-looking statements. These risks and uncertainties include
those that are indicated and detailed in Chapter 3 “Risk factors”
of the Universal Registration Document approved by the French
Financial Markets Authority (Autorité des marchés financiers, AMF)
on April 14, 2023, under number R.23-009 and the Amendment to
Universal Registration Document approved by the AMF on April 25,
2023 under number R.23-015. These forward-looking statements are
given only as of the date of this press release and the Group
expressly declines any obligation or commitment to publish updates
or corrections of the forward-looking statements included in this
press release in order to reflect any change affecting the
forecasts or events, conditions or circumstances on which these
forward-looking statements are based.
_____________________________ 1 Good Manufacturing Practice 2
Chemistry, manufacturing and controls
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240124099563/en/
Media Relations Contact: Laurence Bollack Mob.: +33 (0)6
81 86 80 19 mr@euroapi.com Laurence Jung
laurence.jung@spirochem.com Investor Relations Contact:
Sophie Palliez-Capian Mob.: +33 (0)6 87 89 33 51
sophie.palliez@euroapi.com Thomas Fessard
thomas.fessard@spirochem.com
Euroapi (EU:EAPI)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
Euroapi (EU:EAPI)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024